-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

Benzinga·08/06/2026 13:48:35
語音播報
Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.